The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Arun Azad
Leadership - Chair of the Translational Research Subcommittee and on the Scientific Advisory Committee for the ANZUP Cancer Trials Group; Chair of the Urologic Oncology Group for the Clinical Oncology Society of Australia
Honoraria - Aculeus Therapeutics; Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Research Funding - Aptevo Therapeutic (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Novartis; Pfizer; Tolmar
Other Relationship - medical writing services support from Astellas Pharma, Exelixis and Pfizer; participation on a data safety monitoring board for OncoSec
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
Ugo De Giorgi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck; MSD; Novartis; Pfizer; PharmaMar
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Ipsen; Merck; Pfizer
 
Jae Young Joung
No Relationships to Disclose
 
Peter Fong
Consulting or Advisory Role - MSD
Travel, Accommodations, Expenses - Pfizer
 
Robert Jones
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Elsevier; Ipsen; Janssen; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech; WebMD
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; IPSEN; Janssen; Merck Serono; MSD Oncology; Pfizer
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Janssen; Merck Serono; MSD; Pfizer
 
Stefanie Zschaebitz
Honoraria - Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Eisai Germany; Ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Novartis; Pfizer (Inst)
Consulting or Advisory Role - Amgen; Astellas Pharma (Inst); AstraZeneca; Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai; EUSA Pharma; Gilead Sciences; Ipsen; Merck; MSD Oncology; Pfizer (Inst); Roche; Sanofi/Aventis (Inst)
Research Funding - Eisai (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Ipsen; Janssen Oncology; Merck; Pfizer
 
Jan Oldenburg
Honoraria - Astellas Pharma; AstraZeneca; Bayer; BMS Norway; Eisai; Ipsen; Janssen-Cilag; Merck; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck; Roche
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; BMS Norway; Eisai; Ipsen; Janssen-Cilag; Merck; Roche
Travel, Accommodations, Expenses - Astellas Pharma
 
Neal Shore
Employment - GenesisCare
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Peerview; Pfizer; Photocure; PlatformQ Health; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
 
Curtis Dunshee
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Pfizer
Research Funding - AstraZeneca; Bayer; Dendreon; Hengrui Pharmaceutical; Janssen; Laekna Therapeutics; Myovant Sciences; Pfizer
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
Other Relationship - Catalan Program of Ambulatory Medication Comission (CAHMDA)
 
Andr Poisl Fay
Stock and Other Ownership Interests - Brazilian Information Oncology
Honoraria - Astellas Pharma; AstraZeneca; Bristol Myers Squibb Foundation; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Bayer; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; CAPES-CNPq; Foundation Medicine; Ipsen; MSD; Roche
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche
 
Paul Cislo
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Cynthia Healy
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Melissa Kirker
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Novartis; Pfizer